| BMI1 Drives Metastasis of Prostate Cancer in Caucasian and African-American Men and Is A Potential Therapeutic Target: Hypothesis Tested in Race-specific … AA Ganaie, FH Beigh, M Astone, MG Ferrari, R Maqbool, S Umbreen, ... Clinical Cancer Research 24 (24), 6421-6432, 2018 | 30 | 2018 |
| COMMD3:BMI1 Fusion and COMMD3 Protein Regulate C-MYC Transcription: Novel Therapeutic Target for Metastatic Prostate Cancer S Umbreen, MM Banday, A Jamroze, AP Mansini, AA Ganaie, MG Ferrari, ... Molecular Cancer Therapeutics 18 (11), 2111-2123, 2019 | 21 | 2019 |
| Induction of the p53 tumor suppressor in cancer cells through inhibition of cap-dependent translation BRE Harris, D Wang, Y Zhang, M Ferrari, A Okon, MP Cleary, CR Wagner, ... Molecular and cellular biology, 2018 | 17 | 2018 |
| Anti-S100A4 Antibody Therapy Is Efficient in Treating Aggressive Prostate Cancer and Reversing Immunosuppression: Serum and Biopsy S100A4 as a Clinical … AA Ganaie, AP Mansini, T Hussain, A Rao, HR Siddique, A Shabaneh, ... Molecular cancer therapeutics 19 (12), 2598-2611, 2020 | 12 | 2020 |
| Identifying and treating ROBO1−ve/DOCK1+ve prostate cancer: An aggressive cancer subtype prevalent in African American patients MG Ferrari, AA Ganaie, A Shabenah, AP Mansini, L Wang, P Murugan, ... The Prostate 80 (13), 1045-1057, 2020 | 8 | 2020 |
| Characterization of novel murine and human PDAC cell models: identifying the role of intestine specific homeobox gene ISX in hypoxia and disease progression AA Ganaie, A Parray, T Hussain, A Shabaneh, A Jamroze, MG Ferrari, ... Translational Oncology 12 (8), 1056-1071, 2019 | 4 | 2019 |
| Clinically relevant humanized mouse models of metastatic prostate cancer facilitate therapeutic evaluation RJ Kostlan, JT Phoenix, A Budreika, MG Ferrari, N Khurana, JE Choi, ... Molecular Cancer Research 22 (9), 826-839, 2024 | 1 | 2024 |
| Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential … MG Ferrari, AP Jimenez-Uribe, L Wang, LH Hoeppner, P Murugan, ... Oncogene 43 (7), 484-494, 2024 | 1 | 2024 |
| Clinically relevant humanized mouse models of metastatic prostate cancer to evaluate cancer therapies RJ Kostlan, JT Phoenix, A Budreika, MG Ferrari, N Khurana, JE Cho, ... bioRxiv, 2023 | | 2023 |
| Myeloid differentiation factor-2/LY96, a new predictive biomarker of metastasis in prostate cancer: Clinical implications as a potential therapeutic target M Ferrari, L Wang, L Hoeppner, E Hahm, J Yu, T Kuzel, A Mansini Research Square, 2023 | | 2023 |
| Identification of a Novel Aggressive CD52+ Tumor Cell Subpopulation in Metastatic Prostate Cancer MG Ferrari, P Murugan, TM Kuzel, E Hahm, J Yu, SA Gradilone, ... Fortune Journal of Health Sciences 6, 494-507, 2023 | | 2023 |
| Identifying and treating robo1−ve/dock1+ve prostate cancer: An aggressive cancer type highly prevalent in African-American patients MG Ferrari, A Ganaie, AP Mansini, M Saleem Cancer Research 80 (16_Supplement), 5014-5014, 2020 | | 2020 |
| Identifying a novel and aggressive CD52+ ve type of prostate cancer: Phenotype distinguishing biomarker and therapeutic target AP Mansini, MG Ferrari, A Ganaie, M Saleem Cancer Research 80 (16_Supplement), 343-343, 2020 | | 2020 |
| Identifying novel genetic mechanism underlying ADT resistance in African American patients AA Ganaie, T Hussain, M Ferrari, M Astone, L Hoeppner, T Schuster, ... Cancer Research 78 (13_Supplement), 5851-5851, 2018 | | 2018 |
Adrian MansiniRush University Medical Center在 rush.edu 的电子邮件经过验证
Adrian MansiniRush University Medical Center在 rush.edu 的电子邮件经过验证